Erythropoiesestimulierende Substanzen: günstiges Sicherheitsprofil bei indikationskonformer Anwendung

Nowrousian, Mohammad R.; Dunst, Jürgen; Vaupel, Peter

doi:10.1007/s00066-008-1841-3

Cited by 22 publications

(21 citation statements)

References 151 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only increases up to the currently recommended target Hb levels result in improvements in tumor oxygenation, and thus may improve prognosis. ESAs should be used as indicated and within the current European Organization for Research and Treatment of Cancer guidelines to achieve the optimum Hb levels [37]. …”

Section: Resultsmentioning

confidence: 99%

Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis

2008

Self Cite

View full text Add to dashboard Cite

Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of

show abstract

Section: Resultsmentioning

confidence: 99%

Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis

2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Adding to this concern are certain clinical trials that reported an association with recombinant human Epo (rHuEpo) treatment and possible tumor progression in patients with head and neck, breast, cervical, and ovarian cancers. 4,5 Many of the reports of high levels of EpoR were based on the detection of EpoR mRNA by nonquantitative reverse transcriptasepolymerase chain reaction (RT-PCR) methodologies or by Western blot analysis and/or immunohistochemical (IHC) staining with anti-EpoR antibodies. Conclusions that EpoR was functionally expressed in tumor cell lines were based on EpoR knockdown, 6,7 signaling, 6,8,9 or proliferation studies.…”

Section: Introductionmentioning

confidence: 99%

Absence of functional EpoR expression in human tumor cell lines

Swift¹,

Ellison²,

Kassner³

et al. 2010

Blood

102

View full text Add to dashboard Cite

“…The presence of active EpoR in tumor tissues might promote cancer growth and thus have a negative clinical outcome in patients (14,15). This hypothesis is underlined by clinical trials demonstrating worse survival rates in rhuEpo-treated lung cancer patients than in control patients (16,17), depending on the treatment schedule (18). Further studies were initiated to elucidate the link between rhuEpo treatment and cancer growth but have not provided clear evidence so far.…”

mentioning

confidence: 99%